Search Results
Aug 26, 2026, 10:49 ET Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
Pharmaceuticals (acquired by Sanofi). Dr. Waksal is also the founder and former CEO of ImClone Systems (acquired by Eli Lilly) and a founder of MeiraGTx (NASDAQ: MGTX).Forward-Looking StatementsThis press release contains forward-looking statements regarding Graviton's development plans, regulatory
More news about: Graviton BioScience Corporation
Aug 11, 2026, 10:30 ET Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
Pharmaceuticals (acquired by Sanofi). Dr. Waksal is also the founder and former CEO of ImClone Systems (acquired by Eli Lilly) and a founder of MeiraGTx (NASDAQ: MGTX).Forward-Looking StatementsThis press release contains forward-looking statements regarding Graviton's development plans, regulatory
More news about: Graviton Bioscience Corporation
Feb 03, 2026, 08:00 ET ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
-- ZipBio, a biotechnology company pioneering AI-driven protein therapeutics, announced an exclusive license agreement with MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company. Under the agreement, MeiraGTx will receive exclusive rights to ZipBio's first-in-class
More news about: ZipBio
Nov 20, 2025, 15:00 ET Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference
MGTX). Forward-Looking Statements This press release contains forward-looking
More news about: Graviton Bioscience